| 摘要 |
The present invention relates to an oral dosage form comprising a crystalline form of imatinib mesylate as active agent in order to be used in the treatment of diseases such as acute lymphocytic leukemia, gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome, chronic myelogenous leukemia (CML), myelodysplastic syndrome and systemic mastocytosis; and production of said oral dosage form. |
